Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24555477 | 0.91 | NPC1 (0.43) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL779443 | 0.87 | NPC1 (0.58) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL19002400 | 0.84 | LTA4H (0.47) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL21791678 | 0.82 | NPC1 (0.50) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL19232109 | 0.81 | CNR2 (0.42) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL15294399 | 0.80 | NPC1 (0.48) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL14625003 | 0.80 | ESR1 (0.45) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL5552840 | 0.79 | NPC1 (0.52) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL3625528 | 0.79 | NPC1 (0.52) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL3292125 | 0.79 | NPC1 (0.52) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| WO-2024150676-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION | 富士フイルム株式会社 | 2024-07-18 | — | — | WO | disclosed |
| US-20230384677-A1 | ONIUM SALT COMPOUND, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230303544-A1 | LMO2 PROTEIN INHIBITORS | UNIV OF OXFORD (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230255950-A1 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | GEORGIA TECH RESEARCH CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230226040-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7615316-B2 | Nonaqueous electrolytic solution and lithium secondary batteries | UBE INDUSTRIES, LTD. (JP) | 2009-11-10 | — | — | US | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| EP-1361622-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERIES | UBE INDUSTRIES (JP) | 2008-06-04 | — | — | EP | disclosed |
| US-20080050658-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERIES | UBE INDUSTRIES, LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-7294436-B2 | Nonaqueous electrolytic solution and lithium secondary batteries | UBE INDUSTRIES, LTD. (JP) | 2007-11-13 | — | — | US | disclosed |
| CN-1249840-C | Nonaqueous electrolyte solution and lithium secondary battery | UBE INDUSTRIES (JP) | 2006-04-05 | — | — | CN | disclosed |
| US-20040121239-A1 | Nonaqueous electrolytic solution and lithium secondary batteries | UBE INDUSTRIES, LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| CN-1498438-A | Nonaqueous electrolyte solution and lithium secondary battery | ��˲���ʽ���� | 2004-05-19 | — | — | CN | disclosed |
| EP-1361622-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERIES | Ube Industries, Ltd. (JP) | 2003-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255950-A1 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | KDM1B, KDM3A, KDM1A | NPC1 4132/4885RAB9A 3914/4885MAPT 3227/4885 |
| US-20230303544-A1 | LMO2 PROTEIN INHIBITORS | LMNB2, LMNB1, TPX2 | NPC1 3032/4885RAB9A 3250/4885MAPT 2968/4885 |
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | NPC1 3164/4885RAB9A 1562/4885MAPT 3429/4885 |
| US-20230384677-A1 | ONIUM SALT COMPOUND, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS | INSR, INSRR, SLC6A5 | NPC1 3749/4885RAB9A 3054/4885MAPT 714/4885 |
| US-20230226040-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | KRAS, FGFR2, FGFR3 | NPC1 4429/4885RAB9A 237/4885MAPT 4526/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | NPC1 3237/4885RAB9A 1648/4885MAPT 4584/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | NPC1 2158/4885RAB9A 628/4885MAPT 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.